Showing results (11-20 of 44) with videos related to
Sort By:
Pageof 5
Diabetology & Metabolic Syndrome|September 15, 2015
Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in miceLotta K Stenman, Aurélie Waget, Céline Garret, et al.Diabetes|May 22, 2016
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL CatabolismFrançois Briand, Eric Mayoux, Emmanuel Brousseau, et al.European Journal of Pharmacology|July 5, 2020
Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat modelFrançois Briand, Emmanuel Brousseau, Julie Maupoint, et al.Current Pharmaceutical Design|April 18, 2013
Cardiac dysfunction in rats with dietary-induced insulin resistance associated with pharmacologically-induced dyslipidemiaStéphane Tanguy, Marie-Claire Toufektsian, Stéphane Grauzam, et al.American Journal of Physiology. Gastrointestinal and Liver Physiology|August 29, 2019
Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitisThibaut Duparc, François Briand, Charlotte Trenteseaux, et al.Plos One|November 11, 2014
Deletion of apoptosis signal-regulating kinase 1 (ASK1) protects pancreatic beta-cells from stress-induced death but not from glucose homeostasis alterations under pro-inflammatory conditionsEmilie Pepin, Arisa Higa, Carole Schuster-Klein, et al.European Journal of Clinical Investigation|February 9, 2011
Diet-induced dyslipidemia impairs reverse cholesterol transport in hamstersMorgan Tréguier, François Briand, Adamou Boubacar, et al.European Journal of Pharmacology|July 13, 2025
Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALDFrançois Briand, Caroline Dubroca, Guillaume Wettstein, et al.European Journal of Pharmacology|July 17, 2019
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozinSisse Andersen Nørgaard, François Briand, Fredrik Wolfhagen Sand, et al.Cardiovascular Drugs and Therapy|September 30, 2005
AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in ratsCorinne Berthonneche, Thierry Sulpice, Stéphane Tanguy, et al.Pageof 5